Barclays analyst Luke Sergott lowered the firm’s price target on Illumina (ILMN) to $130 from $145 and keeps an Equal Weight rating on the shares. The firm says the life science tools group will likely continue to work overall on the last estimate cut thesis and Q1 guides “coming in very conservative” that makes it hard to see companies missing targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Cathie Wood’s ARK Investment buys 11.5K shares of Illumina today
- Lilly cuts FY24 outlook, United Rentals to acquire H&E: Morning Buzz
- Illumina sees FY25 non-GAAP EPS growth of 10%
- Illumina sees Q4 EPS 91c-93c, consensus 92c